Skip to main content
 
January 15, 2015
Data presented at Keystone Symposium for Precision Genome Engineering and Synthetic Biology

Caribou Biosciences, a developer of technology-based solutions for cellular engineering, today announced the presentation of new findings demonstrating the advancement of its proprietary CRISPR-Cas9 gene editing and repair technology platform. These findings were presented this week in two poster sessions at The Keystone Symposium for Precision Genome Engineering and Synthetic Biology in Big Sky, Montana.

January 7, 2015
Companies to explore promise of CRISPR as a drug discovery research tool

Caribou Biosciences, a developer of technology-based solutions for cellular engineering, today announced that it entered into a collaboration agreement with Novartis under which the two companies will utilize Caribou's proprietary CRISPR-Cas9 platform to research new CRISPR-based drug target screening and validation technologies.

November 18, 2014
Newly formed company has licensed Caribou technology to advance CRISPR-Cas9 for therapeutic development

Caribou Biosciences, a developer of technology-based solutions for cellular engineering, today announced the launch of Intellia Therapeutics, a new company created by Caribou and Atlas Venture. Intellia will utilize Caribou’s proprietary CRISPR-Cas9 gene editing and repair technology platform in the development of new therapies targeting a variety of genetic-based diseases.

Pages